Abdelmoula WM, Regan MS, Lopez BGC, Randall EC, Lawler S, Mladek AC, Nowicki MO, Marin BM, Agar JN, Swanson KR et al..  2019.  Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data.. Anal Chem. 91(9):6206-6216.

Gampa G, Kim M, Mohammad AS, Parrish KE, Mladek AC, Sarkaria JN, Elmquist WF.  2019.  Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases.. J Pharmacol Exp Ther. 368(3):446-461.

Kim M, Laramy JK, Mohammad AS, Talele S, Fisher J, Sarkaria JN, Elmquist WF.  2019.  Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and -Deficient Mice.. Drug Metab Dispos. 47(4):393-404.

Massey SC, Hawkins-Daarud A, Gallaher J, Anderson ARA, Canoll P, Swanson KR.  2019.  Lesion Dynamics Under Varying Paracrine PDGF Signaling in Brain Tissue.. Bull Math Biol.

Basu SS, McMinn MH, Lopez BGimenez-Ca, Regan MS, Randall EC, Clark AR, Cox CR, Agar NYR.  2019.  Metal Oxide Laser Ionization Mass Spectrometry Imaging (MOLI MSI) Using Cerium(IV) Oxide.. Anal Chem. 91(10):6800-6807.

Koohi-Moghadam M, Borad M, Tran N, Swanson K, Boardman L, Sun H, Wang J.  2019.  MetaMarker: a de novo pipeline for discovering novel metagenomic biomarkers.. Bioinformatics.

White FM, Gatenby RA, Fischbach C.  2019.  The Physics of Cancer.. Cancer Res. 79(9):2107-2110.

Hawkins-Daarud A, Johnston SK, Swanson KR.  2019.  Quantifying Uncertainty and Robustness in a Biomathematical Model-Based Patient-Specific Response Metric for Glioblastoma.. JCO Clin Cancer Inform. 3:1-8.

Basu SS, Regan MS, Randall EC, Abdelmoula WM, Clark AR, Lopez BGimenez-Ca, Cornett DS, Haase A, Santagata S, Agar NYR.  2019.  Rapid MALDI mass spectrometry imaging for surgical pathology.. NPJ Precis Oncol. 3:17.

Jaeger AM, Stopfer L, Lee S, Gaglia G, Sandel D, Santagata S, Lin NU, Trepel JB, White F, Jacks T et al..  2019.  Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation.. Clin Cancer Res. 25(21):6392-6405.

Schwill M, Tamaskovic R, Gajadhar AS, Kast F, White FM, Plückthun A.  2019.  Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.. Sci Signal. 12(565)

Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF.  2018.  Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.. Pharm Res. 35(9):177.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK et al..  2018.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 20(2):184-191.

Bergmann S, Lawler SE, Qu Y, Fadzen CM, Wolfe JM, Regan MS, Pentelute BL, Agar NYR, Cho C-F.  2018.  Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics.. Nat Protoc. 13(12):2827-2843.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.  2018.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.. Drug Metab Dispos. 46(5):658-666.

Juliano J, Gil O, Hawkins-Daarud A, Noticewala S, Rockne RC, Gallaher J, Massey SC, Sims PA, Anderson ARA, Swanson KR et al..  2018.  Comparative dynamics of microglial and glioma cell motility at the infiltrative margin of brain tumours.. J R Soc Interface. 15(139)

Rayfield CA, Grady F, De Leon G, Rockne R, Carrasco E, Jackson P, Vora M, Johnston SK, Hawkins-Daarud A, Clark-Swanson KR et al..  2018.  Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival.. JCO Clin Cancer Inform. 2:1-14.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F et al..  2018.  Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.. Mol Cancer Ther. 17(9):1893-1901.

Roos A, Dhruv HD, Peng S, Inge LJ, Tuncali S, Pineda M, Millard N, Mayo Z, Eschbacher JM, Loftus JC et al..  2018.  EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.. Mol Cancer Res.

Basu SS, Randall EC, Regan MS, Lopez BGC, Clark AR, Schmitt ND, Agar JN, Dillon DA, Agar NYR.  2018.  In Vitro Liquid Extraction Surface Analysis Mass Spectrometry (ivLESA-MS) for Direct Metabolic Analysis of Adherent Cells in Culture.. Anal Chem. 90(8):4987-4991.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL et al..  2018.  Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.. Nat Commun. 9(1):4904.

Prahl LS, Bangasser PF, Stopfer LE, Hemmat M, White FM, Rosenfeld SS, Odde DJ.  2018.  Microtubule-Based Control of Motor-Clutch System Mechanics in Glioma Cell Migration.. Cell Rep. 25(9):2591-2604.e8.

Laramy JK, Kim M, Parrish KE, Sarkaria JN, Elmquist WF.  2018.  Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.. J Pharmacol Exp Ther. 365(2):249-261.

Rothenberg DA, J Taliaferro M, Huber SM, Begley TJ, Dedon PC, White FM.  2018.  A Proteomics Approach to Profiling the Temporal Translational Response to Stress and Growth.. iScience. 9:367-381.

Emdal KB, Dittmann A, Reddy RJ, Lescarbeau RS, Moores SL, Laquerre S, White FM.  2017.  Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.. Mol Cancer Ther. 16(11):2572-2585.